Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX), and a Neutral ...

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

Pharmaceutical tariffs could increase drug prices and drug shortages, negatively impacting the health care system, experts warn.

We previously reported on an uptick in the passage of state drug price transparency legislation. What follows is an update to that report. As of ...

FDA’s recent focus on potentially harmful color additives in food products has expanded to the pharmaceutical sector. In May ...

President Donald J. Trump just released his second executive order (EO) addressing high prescription drug prices. This is ...

NPPA sets retail prices for 41 drug combinations, including 18 variants of off-patent diabetes drug empagliflozin, following steep price drops post-patent expiry ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

By a News Reporter-Staff News Editor at Health Policy and Law Daily-- A new study finds that CivicaScript, a not-for-profit drug manufacturer in the US, can reliably supply essential generic medicines ...

President Trump’s aim to slash U.S. prescription drug prices by 50% is unlikely to materialize, according to analysts at Capital Economics.

PBMs almost never disclose the total discounts they negotiate on specific drugs. So patients' cost-sharing obligations are ...